Form 4: Voyager Therapeutics Director George Scangos Granted 24,000 Stock Options

Voyager Therapeutics, Inc. Director George A. Scangos was granted 24,000 stock options with an exercise price of $3.28, as part of the company's 2025 Stock Incentive Plan.

Summary

• Director George A. Scangos of Voyager Therapeutics, Inc. acquired 24,000 stock options.
• The stock options have an exercise price of $3.28 per share.
• The transaction date, which is also the grant date and vesting commencement date, is June 3, 2025.
• The options are set to expire on June 3, 2035.
• Vesting of the options will occur upon the earlier of the one-year anniversary of the vesting commencement date or the date of the next annual meeting of stockholders, contingent on Mr. Scangos's continued service as a director.
• This grant was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. and aligns with its director compensation policy.

Sentiment

Score: 7

Explanation: The filing reports a standard and expected compensation grant to a director, which is a positive for corporate governance and incentive alignment, but not a significant market-moving event on its own.

Positives

• The grant of stock options to a director helps align their financial interests with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of a formal 2025 Stock Incentive Plan and director compensation policy, indicating structured and transparent governance.

Risks

• The vesting of the stock options is conditional on the director's continued service, meaning the options could be forfeited if service ceases before the vesting conditions are met.

Future Outlook

The vesting schedule for the granted stock options indicates a future potential increase in the director's beneficial ownership of common stock, contingent upon their continued service to the company.

Management Comments

• This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy.

Industry Context

Granting stock options to directors is a common and widely accepted practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, to incentivize and retain key leadership by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to directors as part of their compensation is a standard corporate governance practice across various industries, including biotech.
• The specific terms, such as the number of options and exercise price, would typically be benchmarked against peer companies of similar size and stage within the biopharmaceutical industry, though this document does not provide such comparative data.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from enhanced alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is mentioned in this specific filing.

Next Steps

• The stock options will vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, subject to the director's continued service.
• The director may choose to exercise these vested options at any time before their expiration date of June 3, 2035.

Key Dates

Recommendation

Keywords

Voyager Therapeutics, VYGR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Incentive Plan, Corporate Governance